Pentixapharm Announces Progress of Pivotal Phase 3 PANDA Study; Will Host Third Quarter Webcast on November 12, 2026
Key Highlights
- ➤PANDA protocol receives no FDA comments, including approximately 325 planned patients
- ➤Central U.S. ethics committee approves PANDA protocol and consent documents
- ➤First patient enrollment remains expected in the first quarter of 2027
- ➤Pentixapharm will report third-quarter and nine-month 2026 results November 12
Pentixapharm Announces Progress of Pivotal Phase 3 PANDA Study; Will Host Third Quarter Webcast on November 12, 2026 PR Newswire
* No FDA comments on the study protocol submitted in August 2026, including the primary endpoints and the planned number of approximately 325 patients; central U.S. ethics committee has approved the protocol and consent documents * First patient enrollment continues to be expected in the first quarter of 2027; no material impact on the further study timeline expected * Webcast on third quarter and first nine months 2026 results and PANDA study on November 12, 2026, at 3 p.m. CET BERLIN, Nov. 4, 2026 /PRNewswire/ -- Pentixapharm Holding AG (Frankfurt Prime Standard: PTP), a clinical-stage biotechnology company developing innovative radiopharmaceutical diagnostics and therapeutics, has completed further key preparations towards the start of its pivotal Phase 3 PANDA study. The Company will publish its third quarter and first nine months of 2026 results on Thursday, November 12, 2026.
Get started
Create a free account to read the full story.